QQQ   426.76 (+0.22%)
AAPL   167.96 (-0.02%)
MSFT   408.77 (-0.75%)
META   508.84 (+2.97%)
GOOGL   155.93 (+0.30%)
AMZN   181.54 (+0.14%)
TSLA   151.26 (-2.70%)
NVDA   852.25 (+1.42%)
AMD   155.70 (+1.09%)
NIO   4.03 (+3.07%)
BABA   69.31 (+0.71%)
T   16.15 (+0.19%)
F   12.10 (+0.50%)
MU   116.63 (+0.26%)
GE   157.77 (+1.35%)
CGC   7.04 (+8.47%)
DIS   113.63 (+0.61%)
AMC   2.83 (-5.03%)
PFE   25.39 (-0.12%)
PYPL   63.02 (-0.38%)
XOM   118.81 (+0.15%)
QQQ   426.76 (+0.22%)
AAPL   167.96 (-0.02%)
MSFT   408.77 (-0.75%)
META   508.84 (+2.97%)
GOOGL   155.93 (+0.30%)
AMZN   181.54 (+0.14%)
TSLA   151.26 (-2.70%)
NVDA   852.25 (+1.42%)
AMD   155.70 (+1.09%)
NIO   4.03 (+3.07%)
BABA   69.31 (+0.71%)
T   16.15 (+0.19%)
F   12.10 (+0.50%)
MU   116.63 (+0.26%)
GE   157.77 (+1.35%)
CGC   7.04 (+8.47%)
DIS   113.63 (+0.61%)
AMC   2.83 (-5.03%)
PFE   25.39 (-0.12%)
PYPL   63.02 (-0.38%)
XOM   118.81 (+0.15%)
QQQ   426.76 (+0.22%)
AAPL   167.96 (-0.02%)
MSFT   408.77 (-0.75%)
META   508.84 (+2.97%)
GOOGL   155.93 (+0.30%)
AMZN   181.54 (+0.14%)
TSLA   151.26 (-2.70%)
NVDA   852.25 (+1.42%)
AMD   155.70 (+1.09%)
NIO   4.03 (+3.07%)
BABA   69.31 (+0.71%)
T   16.15 (+0.19%)
F   12.10 (+0.50%)
MU   116.63 (+0.26%)
GE   157.77 (+1.35%)
CGC   7.04 (+8.47%)
DIS   113.63 (+0.61%)
AMC   2.83 (-5.03%)
PFE   25.39 (-0.12%)
PYPL   63.02 (-0.38%)
XOM   118.81 (+0.15%)
QQQ   426.76 (+0.22%)
AAPL   167.96 (-0.02%)
MSFT   408.77 (-0.75%)
META   508.84 (+2.97%)
GOOGL   155.93 (+0.30%)
AMZN   181.54 (+0.14%)
TSLA   151.26 (-2.70%)
NVDA   852.25 (+1.42%)
AMD   155.70 (+1.09%)
NIO   4.03 (+3.07%)
BABA   69.31 (+0.71%)
T   16.15 (+0.19%)
F   12.10 (+0.50%)
MU   116.63 (+0.26%)
GE   157.77 (+1.35%)
CGC   7.04 (+8.47%)
DIS   113.63 (+0.61%)
AMC   2.83 (-5.03%)
PFE   25.39 (-0.12%)
PYPL   63.02 (-0.38%)
XOM   118.81 (+0.15%)
Free Trial
NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)
Free TALS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$16.30
▼
$17.94
50-Day Range
$12.36
▼
$28.36
52-Week Range
$0.89
▼
$27.95
Volume
591,944 shs
Average Volume
386,531 shs
Market Capitalization
$713.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSocial Media
TALS stock logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Stock News Headlines

February 25, 2024 | benzinga.com
Longitude Venture Partners III, L.P.'s Net Worth
November 1, 2023 | msn.com
Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15
April 18, 2024 | DTI (Ad)
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
October 19, 2023 | msn.com
Talaris Therapeutics goes ex-dividend tomorrow
October 18, 2023 | finanznachrichten.de
Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 17, 2023 | msn.com
Talaris shareholders approve merger, 1-for-10 reverse stock split
October 17, 2023 | finance.yahoo.com
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 6, 2023 | marketwatch.com
Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger
April 18, 2024 | DTI (Ad)
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
October 6, 2023 | finance.yahoo.com
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
October 4, 2023 | finance.yahoo.com
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
September 12, 2023 | finance.yahoo.com
We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
August 15, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT
August 14, 2023 | finance.yahoo.com
ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business
August 8, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF
July 28, 2023 | benzinga.com
Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm
July 27, 2023 | markets.businessinsider.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)
July 18, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS
July 18, 2023 | msn.com
Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger
July 6, 2023 | msn.com
Talaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75
June 27, 2023 | markets.businessinsider.com
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI
June 26, 2023 | businesswire.com
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
June 23, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. Merger
June 23, 2023 | bizjournals.com
Talaris Therapeutics announces merger after layoffs
June 22, 2023 | bizjournals.com
NY biotech to go public by merging with Boston firm that laid off 95% of staff
June 22, 2023 | msn.com
Talaris jumps 29% on merger with Tourmaline Bio in all-stock deal
June 22, 2023 | markets.businessinsider.com
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
See More Headlines
Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
CUSIP
N/A
CIK
1827506
Web
talaristx.com
Phone
502-398-9250
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-73,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.93%
Return on Assets
-37.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.41
Quick Ratio
15.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
3.85

Miscellaneous

Outstanding Shares
42,764,000
Free Float
35,708,000
Market Cap
$713.30 million
Optionable
Not Optionable
Beta
2.18
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

TALS Stock Analysis - Frequently Asked Questions

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?

Talaris Therapeutics declared a dividend on Thursday, October 19th. Stockholders of record on Monday, October 16th will be given a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date is Friday, October 20th.
Read our dividend analysis for TALS.

When did Talaris Therapeutics IPO?

Talaris Therapeutics (TALS) raised $150 million in an initial public offering (IPO) on Friday, May 7th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.

This page (NASDAQ:TALS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Urgent alert: open this for a huge profit potential
Timothy Sykes
Options trading has suddenly become more reliable.
Eagle Publishing
The Greatest Bull Market in Crypto History…
Weiss Ratings